For chiral drug molecules only one enantiomer (the eutomer)

will fit properly into this receptor, resulting in the desired therapeutic effect. The other enantiomer (the distomer) can either not interact or can interact less intense with the receptor, which generally causes a lower effect. Occasionally the distomer interacts with other receptors, causing side or even toxic effects. As a consequence, the enantiomers of drug candidates must be subjected to supplementary investigations during development selleck kinase inhibitor processes: the eutomer has to be distinguished from the distomer during identification and impurity determinations of the drug substance. For drug products, it should be confirmed that the eutomer is present in the required dose while the distomer level should be analyzed as impurity, as prescribed in the guidelines imposed by the International Conference on Harmonisation (ICH), more precisely in guideline Q6A (decision tree number 5).3 and 4 According to the regulatory authorities, an enantioselective HPLC method should be able to separate the optically see more active drug substance from the enantiomeric impurity and other potential organic impurities. Potential organic impurities include chiral and/or achiral starting materials, intermediates and by-products from the drug substance manufacturing

process. Enantiomers are strictly similar in structure to the active product ingredient (API). So, a chemo-and enantioselective HPLC purity appears a critical step in the development of high-quality manufacturing processes and quality-control methods. Dichloromethane dehalogenase Sitagliptin Phosphate is chemically 7-[(3R)-3-amino-1-oxo-4-(2,4,5 trifluorophenyl) butyl]-5,6,7,8-tetrahydo-3-(trifluoromethyl)-1,2,4-Triazolo

[4,3-a] pyrazine phosphate (1:1) monohydrate (Fig. 1),an oral anti-diabetic agent that blocks dipeptidylpeptidase-4 (DPP-4) activity. Currently it is available in the market under the brand name of Januvia. Januvia is an orally-active inhibitor of the dipeptidylpeptidase-4 (DPP-4) enzyme. The DPP-4 enzyme inactivates incretin hormones, which are involved in the physiologic regulation of glucose homeostasis. By inhibiting DPP-4, Januvia increases and prolongs active incretin levels. This in turn increases insulin release and decreases glucagon levels in the circulation in a glucose-dependent manner. Januvia is specifically indicated for the improvement of glycemic control in patients with type II diabetes mellitus as monotherapy or combination therapy with metformin or a peroxisome proliferator activated receptor gamma (PPAR) agonist (e.g., thiazolidinediones) when the single agent does not provide adequate glycemic control. Several HPLC methods are reported for determination of sitagliptin phosphate in tablet dosage and combination with other drugs in pharmaceutical formulation, and plasma.